| Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice JO McNamara, D Kolonias, F Pastor, RS Mittler, L Chen, PH Giangrande, ... The Journal of clinical investigation 118 (1), 376-386, 2008 | 357 | 2008 |
| Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay F Pastor, D Kolonias, PH Giangrande, E Gilboa Nature 465 (7295), 227-230, 2010 | 323 | 2010 |
| Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS MF Sanmamed, F Pastor, A Rodriguez, JL Perez-Gracia, ... Seminars in oncology 42 (4), 640-655, 2015 | 256 | 2015 |
| An RNA toolbox for cancer immunotherapy F Pastor, P Berraondo, I Etxeberria, J Frederick, U Sahin, E Gilboa, ... Nature Reviews Drug Discovery 17 (10), 751-767, 2018 | 199 | 2018 |
| Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma S Inogès, M Rodrìguez-Calvillo, N Zabalegui, A Lòpez-Dìaz de Cerio, ... Journal of the National Cancer Institute 98 (18), 1292-1301, 2006 | 170 | 2006 |
| Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers F Pastor, D Kolonias, JO McNamara II, E Gilboa Molecular therapy 19 (10), 1878-1886, 2011 | 145 | 2011 |
| A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients S Inogés, S Tejada, ALD de Cerio, J Gállego Pérez-Larraya, J Espinós, ... Journal of translational medicine 15, 1-12, 2017 | 126 | 2017 |
| CD28 aptamers as powerful immune response modulators F Pastor, MM Soldevilla, H Villanueva, D Kolonias, S Inoges, AL De Cerio, ... Molecular therapy-Nucleic acids 2, 2013 | 123 | 2013 |
| Use of oligonucleotide aptamer ligands to modulate the function of immune receptors E Gilboa, J McNamara, F Pastor Clinical cancer research 19 (5), 1054-1062, 2013 | 95 | 2013 |
| Aptamers against live targets: is in vivo SELEX finally coming to the edge? M Sola, AP Menon, B Moreno, D Meraviglia-Crivelli, MM Soldevilla, ... Molecular Therapy-Nucleic Acids 21, 192-204, 2020 | 86 | 2020 |
| 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia MM Soldevilla, H Villanueva, M Bendandi, S Inoges, ALD de Cerio, ... Biomaterials 67, 274-285, 2015 | 73 | 2015 |
| Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma D Tusé, N Ku, M Bendandi, C Becerra, R Collins, N Langford, SI Sancho, ... BioMed Research International 2015, 2015 | 70 | 2015 |
| MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells MM Soldevilla, H Villanueva, N Casares, JJ Lasarte, M Bendandi, ... Oncotarget 7 (17), 23182, 2016 | 67 | 2016 |
| Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy S Hervas-Stubbs, MM Soldevilla, H Villanueva, U Mancheño, M Bendandi, ... Oncotarget 7 (4), 4522, 2016 | 54 | 2016 |
| Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy T Lozano, MM Soldevilla, N Casares, H Villanueva, M Bendandi, ... Biomaterials 91, 73-80, 2016 | 51 | 2016 |
| Aptamer-iRNAs as therapeutics for cancer treatment MM Soldevilla, D Meraviglia-Crivelli de Caso, AP Menon, F Pastor Pharmaceuticals 11 (4), 108, 2018 | 48 | 2018 |
| In silico aptamer docking studies: from a retrospective validation to a prospective case study'tim3 aptamers binding O Rabal, F Pastor, H Villanueva, MM Soldevilla, S Hervas-Stubbs, ... Molecular Therapy-Nucleic Acids 5, 2016 | 47 | 2016 |
| ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity MM Soldevilla, H Villanueva, D Meraviglia-Crivelli, AP Menon, M Ruiz, ... Molecular Therapy 27 (11), 1878-1891, 2019 | 45 | 2019 |
| Aptamers: a feasible technology in cancer immunotherapy MM Soldevilla, H Villanueva, F Pastor Journal of immunology research 2016, 2016 | 42 | 2016 |
| Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14 C Moreno, J Merino, N Ramírez, A Echeverría, F Pastor, ... Microbes and infection 6 (11), 990-995, 2004 | 42 | 2004 |
